Navigation Links
Parios Regenerative Sciences, Inc. Licenses Exclusive Rights to Organic Nanotechnology for Skin Repair
Date:11/1/2012

CONCORD, Mass., Nov. 1, 2012 /PRNewswire/ -- Parios Regenerative Sciences, Inc., a privately held medical device company specializing in the development of biomaterials for skin repair and regeneration, has entered into a comprehensive license agreement with Brown University, licensing exclusive rights to a proprietary organic nanotechnology for use in dermatological applications. The nanotechnology, Oderm™, has clinical relevance in cosmetic skin rejuvenation, dermatological applications, and advanced wound care.

"Our agreement with Brown is a significant milestone for Parios," stated Mark Johanson, President and Chief Executive Officer.  "The Oderm™ technology shows great promise in advancing the field of skin regeneration for both aesthetic and wound care applications. We are committed to the commercial and clinical success of this novel skin care product."

Under the terms of the agreement, Parios has obtained an exclusive license to a platform of intellectual property and technologies co-developed by Dr. Thomas Webster, former associate professor of engineering at Brown.

"We are enthusiastic to have partnered with such an experienced and accomplished team at Parios," said Katherine Gordon, Managing Director of the Brown University Technology Ventures Office, "and look forward to successful development of the product."

The Oderm™ biomaterial consists of organic nanomolecules that self-assemble into structures resembling collagen – a major component of skin. Using these organic structures to replace degenerated or damaged skin encourages the growth of natural tissue. The company's goal is to provide off-the-shelf materials that regenerate healthy and functional tissue and offer a repair that lasts the life of the patient.

About Parios Regenerative Sciences, Inc.

Parios is a privately held company located in Concord, MA focused on the growing market of skin tissue regeneration. The company is developing the Oderm™ product line to compete in the non-invasive skin care market, by offering injectable and topical solutions to stimulate collagen regrowth. Current products are in the preclinical phase of development. With Oderm™ and other advanced biomaterials in the pipeline, Parios offers a modern alternative to existing skin repair therapies.


'/>"/>
SOURCE Parios Regenerative Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regado Biosciences, Inc. to Present at the UBS Global Life Sciences Conference 2012 in New York, NY
2. QPS Acquires JSW Life Sciences, Largest Independent Contract Research Organization in Austria
3. Pressure BioSciences, Inc. Reports 70% Revenue Growth for Second Consecutive Quarter
4. Pressure BioSciences, Inc. to Discuss Second Quarter 2012 Financial Results and Provide Business Update
5. Regado Biosciences, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference in Boston, MA
6. Regado Biosciences, Inc. to Present at the 2012 Wedbush PacGrow Life Sciences Conference in New York, NY
7. Founded by Enlight Biosciences, KNODE partners with AstraZeneca and Other Partners
8. KannaLife Sciences, Inc. Signs Exclusive License Agreement with National Institutes of Health Office of Technology Transfer (NIH-OTT)
9. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
10. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
11. West Health Institute licenses Kinect-based physical therapy technology to Reflexion Health; West Health Investment Fund makes $4.25 million investment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/13/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... the U.S. Food and Drug Administration (FDA) has notified the ... to its Zhejiang, China manufacturing facility ... "The successful clearance of the Warning Letter related to our ... a measure of the progress we have made in our ...
(Date:6/9/2017)... , June 9, 2017 More than ... further effort to help spread lessons learned from clinical ... International Diabetes Federation (IDF) and Eli Lilly and Company ... the second phase of the Bringing Research in Diabetes ... their commitment to helping people with diabetes effectively manage ...
(Date:6/7/2017)... , June 7, 2017  Novavax, Inc., (Nasdaq: ... of two Phase 2 trials of its RSV F protein ... child bearing age have been published in the journal ... have been shared in prior scientific conferences). The Company previously ... April 2014. Novavax is developing the RSV F Vaccine with ...
Breaking Medicine Technology:
(Date:6/20/2017)... ... June 20, 2017 , ... ... , is pleased to announce a new online course entitled Personal & ... practical insights and evidence-based strategies for achieving optimal well-being and teaches students how ...
(Date:6/20/2017)... ... , ... Kenneth Mayer, MD, has been appointed a new Editor-in-Chief of the ... the JIAS Editorial Board in 2016, has co-authored more than 800 peer-reviewed publications. Among ... and Co-Chair of The Fenway Institute, a member of the US President’s Emergency ...
(Date:6/20/2017)... York, NY (PRWEB) , ... June 20, 2017 , ... ... today their continued expansion and success in the clinical trials market. Similar to its ... a track record in the clinical trials marketplace by proving the value of eVisits ...
(Date:6/20/2017)... ... June 20, 2017 , ... Dr. Manju R. Kejriwal ... leading-edge care, whether or not they have a referral. Dr. Kejriwal offers state-of-the-art ... laser, she targets bacteria and damaged tissue without affecting the surrounding tissue. This ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... (AHN) Jefferson Hospital is providing physicians with advanced capabilities for diagnosing and treating ... than traditional MRIs, enabling doctors to get a more accurate look inside the ...
Breaking Medicine News(10 mins):